Skip to main content

Table 4 Statin type and the risk of pneumonia requiring hospitalization within a 90-day exposure

From: Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study

  Controls Cases Crude OR   Adjusteda OR  
  N N (95 % CI) P (95 % CI) P
Overall MI patients 4,778 963 -   -  
Statin type
 Artovastatin 3,242 639 1.00 (Ref.)   1.00 (Ref.)  
 Fluvastatin 556 132 1.21 (0.94–1.56) 0.136 1.14 (0.85–1.52) 0.390
 Simvastatin 510 109 1.04 (0.79–1.38) 0.781 1.19 (0.87–1.64) 0.283
 Other 470 83 0.87 (0.65–1.17) 0.363 0.73 (0.51–1.03) 0.075
MI patients unexposed to statin pretreatment 2,683 403     
Statin type
 Atorvastatin 1,863 270 1.00 (Ref.)   1.00 (Ref.)  
 Fluvastatin 297 55 1.16 (0.71–1.90) 0.549 1.11 (0.6–2.04) 0.743
 Simvastatin 278 54 0.80 (0.49–1.32) 0.386 1.12 (0.59–2.10) 0.729
 Other 245 24 0.65 (0.36–1.17) 0.153 0.66 (0.31–1.41) 0.286
  1. ACEI/ARB angiotensin-converting enzyme inhibitor/angiotensin receptor blockade, CHADS 2 congestive heart failure, hypertension, age > 75 years, diabetes, previous stroke, CI confidence interval; COPD, chronic obstructive pulmonary disease, DDD defined daily dose, DDD 90 average defined daily dose within 90 days, OR odds ratio, PPI proton pump inhibitor, Ref reference group, SD standard deviation
  2. a Adjusted for CHASD2 score, medical conditions (diabetes mellitus, hypertension, chronic heart failure, stroke, COPD, chronic kidney disease, chronic liver disease, Parkinson disease, and dementia) and medication use (antineoplastic drug, PPI, ACEI/ARB, antiviral drug, immunosuppressants, immunostimulants, nitrate, antiplatelet and influenza or pneumococcal vaccine)